{"product_id":"smith-nephew-bcg-matrix","title":"Smith \u0026 Nephew Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Smith \u0026amp; Nephew BCG Matrix maps its core portfolio—orthopaedics, sports medicine, and advanced wound care—into Stars, Cash Cows, Question Marks, and Dogs to clarify where market leadership and resource drains lie. This snapshot highlights which product lines may warrant further investment versus those that could fund growth. Purchase the full BCG Matrix for a complete breakdown and strategic insights you can act on. Buy the full report to receive a detailed Word analysis plus an Excel summary for quick presentation and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCORI surgical robotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024 robotics-assisted knee arthroplasty is a fast-growing segment and CORI gives Smith \u0026amp; Nephew a credible, scaled presence in the space. Installed-base momentum and ASC-friendly workflows sustain high utilization and implant pull-through. Continued software upgrades and indications expansion support share retention as the segment grows. Prioritize investment to defend leadership and convert growth into future cash-cow economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePICO single‑use NPWT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePICO single‑use NPWT is a Star for Smith \u0026amp; Nephew: strong clinical support, brand recognition and broad indications have driven leading share in a niche growing at ≈10% CAGR to 2028. Adoption across inpatient-to-home drove robust 2024 volume growth; group sales were £3.1bn in 2024. Continued funding for market development and outcomes evidence keeps PICO first choice; it is supported by \u0026gt;10 RCTs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSports medicine soft‑tissue repair\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSports medicine soft-tissue repair (shoulder, knee, hip arthroscopy implants and instruments) is a structural growth category for Smith \u0026amp; Nephew and was a star in 2024. Smith \u0026amp; Nephew leads in suture anchors, fixation, access and RF energy for soft-tissue procedures. High procedure volumes and rapid innovation cadence sustain share and growth, while continual portfolio refresh and surgeon training preserve star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREGENETEN bioinductive implant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREGENETEN is a Star: rotator-cuff bioinductive augmentation is scaling fast due to improved outcomes and OR efficiency. REGENETEN, FDA-cleared 2019, has strong surgeon advocacy and brand leadership. With ~250,000 US repairs\/year and accelerating 2024 category growth, prioritize evidence and geographic expansion to compound share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSurgeon advocacy\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFDA clearance 2019\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e~250k US procedures\/year\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvest RCTs \u0026amp; geographies\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOASIS advanced wound matrix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOASIS advanced wound matrix is a Star for Smith \u0026amp; Nephew: biologic collagen matrices are growing faster than traditional dressings. In 2024 OASIS's long clinical heritage and broad reimbursement anchor a strong subsegment share. Utilization is expanding across acute, outpatient and home settings as protocols standardize; ongoing trials and HEOR can support conversion and premium pricing.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eEstablished clinical heritage\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eBroad payer coverage\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eExpanding across care settings\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eOngoing trials and HEOR\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobotic knees drive implants; NPWT ≈10% CAGR; group sales \u003cstrong\u003e£3.1bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCORI robotics anchors Smith \u0026amp; Nephew in fast-growing robotics knee arthroplasty and drives implant pull-through. PICO single-use NPWT leads a ≈10% CAGR niche; group sales £3.1bn in 2024. REGENETEN (FDA 2019) covers ~250,000 US repairs\/year and OASIS shows broad payer coverage across care settings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCORI robotics\u003c\/td\u003e\n\u003ctd\u003eInstalled base; ASC traction\u003c\/td\u003e\n\u003ctd\u003eRobotics knee growth\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePICO NPWT\u003c\/td\u003e\n\u003ctd\u003e≈10% CAGR to 2028; £3.1bn group sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10 RCTs; leading share\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREGENETEN \/ OASIS\u003c\/td\u003e\n\u003ctd\u003e~250k US repairs; broad coverage\u003c\/td\u003e\n\u003ctd\u003eInvest RCTs \u0026amp; HEOR\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSmith \u0026amp; Nephew BCG: Stars (orthopedics) to invest, Cash Cows (wound care) to hold, Question Marks (digital) to evaluate, Dogs to divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Smith \u0026amp; Nephew BCG Matrix that clarifies portfolio priorities, eases resource pain points and exports to C-level slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALLEVYN foam dressings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALLEVYN sits in the mature, high‑volume foam segment where Smith \u0026amp; Nephew holds entrenched positions and broad formulary access, with clinician preference creating stickiness. Global advanced wound care was ~USD 12.0bn in 2024 with foam growing ~3–4% annually; the Advanced Wound Management portfolio was ~£700m in FY2024, delivering attractive margins and strong cash conversion. Maintain supply excellence and incremental innovation to milk dependable cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eACTICOAT antimicrobial dressings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAntimicrobial dressings show stable demand and sustain premium pricing. ACTICOAT’s silver technology and clinical lineage underpin a durable share in a mature market, with the global advanced wound care market estimated at about USD 10.5bn in 2024. Marketing intensity is modest relative to returns, so focus on manufacturing efficiency and contracting discipline to optimize cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIODOSORB\/IODOFLEX iodine range\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIODOSORB\/IODOFLEX iodine gels and dressings address bioburden in chronic wounds and retain long-standing clinical adoption; as of 2024 the category remains established but slow-growing. Smith \u0026amp; Nephew’s franchise continues to be widely specified by clinicians, producing recurring usage patterns that support steady volumes and margins. Optimizing SKU mix and distribution will help sustain reliable free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOBLATION ENT tonsil\/adenoid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCOBLATION ENT tonsil\/adenoid lies in a mature procedural market; the COBLATION brand retains strong surgeon familiarity and clinical adoption. Replacement instruments and consumables drive predictable recurring revenue with low promotional needs. Prioritize lifecycle cost management and service quality to protect profitability.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCOBLATION is a Smith \u0026amp; Nephew brand (2024).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSmith \u0026amp; Nephew reported ~£3.9bn revenue in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eUS tonsillectomy volumes ≈300,000 procedures\/year (widely cited).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on consumable attach rates, service SLAs and cost-to-serve.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLEGION\/JOURNEY knee systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLEGION\/JOURNEY knee systems are cash cows for Smith \u0026amp; Nephew: primary and revision knees sit in a mature implant market with ~700,000 US TKAs and ~1.3M global procedures in 2024, and the installed base delivers steady procedure share. Pricing pressure persists, but mix and scale supported cash generation in 2024; focus on inventory turns and standardization preserves margins.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumables (wound, knee, ENT) underpin margins; revenue \u003cstrong\u003e~£3.9bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eALLEVYN, ACTICOAT, IODOSORB, COBLATION and LEGION\/JOURNEY are cash cows, delivering strong margins and cash conversion within Smith \u0026amp; Nephew’s ~£3.9bn 2024 revenue. Advanced Wound Management was ~£700m in FY2024. Global knees ≈1.3M and US tonsil ≈300k in 2024 underpin steady consumable attach; priorities: supply excellence, SKU rationalization and attach‑rate uplift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eRevenue\/scale\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWound\u003c\/td\u003e\n\u003ctd\u003eAWM ~£700m\u003c\/td\u003e\n\u003ctd\u003eHigh margin, recurring\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eSupply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKnees\u003c\/td\u003e\n\u003ctd\u003eGlobal ≈1.3M\u003c\/td\u003e\n\u003ctd\u003eInstalled base, consumables\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eInventory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eENT\u003c\/td\u003e\n\u003ctd\u003eUS tonsil ≈300k\u003c\/td\u003e\n\u003ctd\u003ePredictable consumables\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eService\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eSmith \u0026amp; Nephew BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact BCG Matrix you'll receive after purchase — no watermarks, no demo content, just a fully formatted, ready-to-use report for strategic clarity. This preview matches the downloadable document and includes market-backed analysis and clear visuals for immediate presentation. After purchase the full file is delivered to your inbox and is editable, printable, and client-ready. Designed by strategy experts, it's ready to plug into business reviews, investor decks, or competitive analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674512900473,"sku":"smith-nephew-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/smith-nephew-bcg-matrix.png?v=1755790747","url":"https:\/\/portersfiveforce.com\/products\/smith-nephew-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}